Amwell exceeded its Q4 2025 financial guidance with total revenue of $55.3 million. The company reported a net loss of ($25.2) million and adjusted EBITDA of ($10.3) million, both showing improvement from the third quarter of 2025. The focus on its Technology Enabled Care platform contributed to strong market validation and contract renewals.
Total revenue for Q4 2025 was $55.3 million, surpassing the financial guidance provided in Q3.
Net loss improved to ($25.2) million in Q4 2025, compared to ($31.9) million in Q3 2025.
Adjusted EBITDA improved to ($10.3) million in Q4 2025, compared to ($12.7) million in Q3 2025.
The company reported a gross margin of 51% for the fourth quarter.
Amwell provided financial guidance for the full year 2026 and for Q1 2026, projecting revenue between $195 million and $205 million for the full year, and between $48 million and $53 million for Q1. The company also aims to achieve positive cash flow from operations by Q4 2026.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance